Standard BioTools, Inc.

As of October 10, 2025, Standard BioTools, Inc. shows a mildly bullish trend overall, supported by weekly and monthly MACD indicators, despite mixed signals from Bollinger Bands and KST.

As of October 10, 2025, Standard BioTools, Inc. shows a mildly bullish trend overall, despite mixed signals from various indicators, and has significantly underperformed the S&P 500 with a return of -27.68% compared to the S&P's 13.36%.

As of September 12, 2025, Standard BioTools, Inc. is in a mildly bearish trend with mixed monthly indicators, showing a 1-week return of 6.02% and a 1-month return of 11.02%, but underperforming year-to-date and over the past year with returns of -19.43% and -30.54%, respectively.

As of June 2, 2025, Standard BioTools, Inc. shows a mildly bearish trend overall, with daily indicators suggesting bearish momentum while weekly signals indicate short-term strength, leading to a cautious market sentiment.

As of March 2022, the management team of Standard BioTools, Inc. includes Dr. Carlos Paya (Independent Chairman), Mr. Stephen Linthwaite (President and CEO), and several Independent Directors: Ms. Ana Stankovic, Mr. Nicolas Barthelemy, Mr. Gerhard Burbach, Ms. Laura Clague, and Dr. Bill Colston. They oversee the company's strategic direction and governance.

Standard BioTools, Inc. develops and commercializes life science tools for single-cell analysis and genomics. As of March 2025, it reported net sales of $41 million and a net loss of $26 million, with a market cap of $387.42 million.

As of Jun 18, Standard BioTools, Inc. has a market capitalization of 387.42 million, with net sales of 169.69 million and a net profit of -132.76 million over the latest four quarters. Shareholder's funds are 471.72 million, and total assets are 612.34 million as of Dec 24.